Cerebral Infarction Drugs Market Size & Share, by Diagnosis (Carotid Ultrasound, Cerebral Angiogram, Echocardiogram); Drug Class {Tissue Plasminogen Activators (tPA), Anticoagulants}; Distribution Channel (Hospitals, Drug Stores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Companies Dominating the Cerebral Infarction Drugs Landscape

top-features-companies
    • Amgen Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Amneal Pharmaceuticals, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Edwards Lifesciences Corporation
    • Daiichi Sankyo Company, Limited

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Abbott Laboratories declared that the FDA has given the approval to its Amplatzer Amulet Left Atrial Appendage Occluder device to treat persons with atrial fibrillation (AFib) who are at a higher risk for an ischemic stroke. The device provides prompt closure of the left atrial appendage (LAA), which lowers stroke risk and prevents the immediate requirement for blood-thinning medicines in persons with AFib.

  • Daiichi Sankyo Company, Limited declared the accomplishment of the primary endpoint in the Japan PRASTRO-III phase 3 study of the antiplatelet agent, prasugrel hydrochloride in thrombotic stroke patients. The clinical study was conducted in a double-blind comparative method to evaluate the effectiveness and safety of prasugrel and clopidogrel in 234 thrombotic stroke patients with one or more risk factors for ischemic stroke recurrence.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide growing prevalence of sedentary lifestyle, rising cases of arterial embolism, and rising ratio of clinical trials and their positive outcomes are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

Risk of side effects associated with the treatment, and low awareness among people in emerging nations regarding the cerebral infarction are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by diagnosis, drug class, distribution channel, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying